Lewis Hsu, Professor at University of Illinois at Chicago, is a pediatric hematologist dedicated to finding more cures for sickle cell disease, and improving treatment and education until cures can be found. He earned his MD and PhD (Biophysics) at University of Rochester, pediatric residency at Yale-New Haven, and pediatric hematology-oncology fellowship at Children’s Hospital of Philadelphia. His clinical and translational research in sickle cell disease include the landmark STOP study of transfusion to reduce stroke risk, bone marrow transplantation for children with severe sickle cell disease, and clinical research on pain management candidate agents. He has 23 years of experience in leadership of some of the largest pediatric sickle cell programs in the country. He strives for close partnership with adult hematology on comprehensive care across the lifespan. He became Vice Chief Medical Officer of Sickle Cell Disease Association of America in Oct 2016. He has over 70 peer-reviewed publications, and co-authored 3 books and 5 websites devoted to patient education. He is co-PI of a site in the NIH Sickle Cell Disease Implementation Consortium with Dr. Gordeuk. He is gaining experience with patient-reported outcomes through projects funded by PCORI (Chicago CAPriCORN network and Transition Care Evidence 2 Action Network). Participating in American Society of Hematology initiatives, legislative advocacy, community health fairs, sickle cell community groups have deepened his appreciation for the multiple concerns of people living with sickle cell. This report was made possible by funding of student research under the ASH Minority Medical Student Award Program.